We are proud to announce the incorporation of Uveren® (Macitentan) into our Pulmonology Division.
This treatment is indicated for the long-term management of pulmonary arterial hypertension (PAH), a rare and complex condition, providing a reliable therapeutic option for patients living with it.
Available presentation:
- Coated tablets of 10 mg.
With the launch of Uveren®, at Aspen Laboratorios we reaffirm our commitment to research, development, and the availability of innovative medicines for diseases that require specialized care.